{
      "Rank": 367,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control.",
            "vildagliptin+metformin+pioglitazone and on Insulin >0.4unit/Kg who will act as active control.They will receive injectable placebo at Day 1 in addition to above and will be followed up for 6 months.Follow up investigation and Insulin dose titration will be similar to Group 1",
            "Patients with Type 2 Diabetes mellitus on full doses of Vildagliptin+Pioglitazone+Metformin and requiring Insulin at dose of >0.4unit/Kg for blood glucose control."
      ],
      "ArmGroupInterventionName": [
            "Biological: mesenchymal stem cell transplantation",
            "Other: control",
            "Biological: MNC's TRANSPLANTATION"
      ],
      "ArmGroupLabel": [
            "mesenchymal stem cell transplantation",
            "Control",
            "MNC's TRANSPLANTATION"
      ],
      "ArmGroupType": [
            "Experimental",
            "Sham Comparator",
            "Experimental"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01759823"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purpose of this study is to improve the blood glucose level in type 2 diabetic patients."
      ],
      "BriefTitle": [
            "Bone Marrow Derived Stem Cell Transplantation in T2DM"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [],
      "CollaboratorName": [],
      "CompletionDate": [
            "October 2015"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Type 2 Diabetes Mellitus"
      ],
      "ConditionAncestorId": [
            "D000044882",
            "D000008659",
            "D000004700"
      ],
      "ConditionAncestorTerm": [
            "Glucose Metabolism Disorders",
            "Metabolic Diseases",
            "Endocrine System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC18",
            "BC19",
            "All"
      ],
      "ConditionBrowseBranchName": [
            "Nutritional and Metabolic Diseases",
            "Gland and Hormone Related Diseases",
            "All Conditions"
      ],
      "ConditionBrowseLeafAsFound": [
            "Diabetes Mellitus",
            "Type 2 Diabetes Mellitus"
      ],
      "ConditionBrowseLeafId": [
            "M6267",
            "M6271",
            "M10791",
            "M24556",
            "M7014"
      ],
      "ConditionBrowseLeafName": [
            "Diabetes Mellitus",
            "Diabetes Mellitus, Type 2",
            "Metabolic Diseases",
            "Glucose Metabolism Disorders",
            "Endocrine System Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000003920",
            "D000003924"
      ],
      "ConditionMeshTerm": [
            "Diabetes Mellitus",
            "Diabetes Mellitus, Type 2"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Single"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant"
      ],
      "DetailedDescription": [
            "We hypothesize that Autologous bone marrow derived stem cells which would be expanded into culture and their subsequent transplant into the pancreas of patients with T2DM, aged 30 - 70 years with triple oral hypoglycemic agent failure and on insulin(>0.4 U/ kg body weight/day) will lead to abolition or reduction of insulin requirement by more than or equal to 50% in these patients over a period of 6 months. It is assumed that stem cell in these patients leads to increased angiogenesis, secretion of various cytokines and upregulation of pancreatic transcription factors and Vascular endothelial growth factor(VEGF) and creates a micro-environment which supports beta cell/resident stem cell activation and survival."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nPatients with type 2 diabetes mellitus between 30 and 70 years of age.\n\nFailure to triple oral hypoglycemic agent and on stable doses of insulin for at least 3 months.\nOn vildagliptin,pioglitazone and metformin for at least 3 months along with Insulin to maintain euglycemia.\nHbA1c < 7.5%.\nInsulin requirement \u22650.4 IU/kg/d.\nGAD antibody negative status.\n\nExclusion Criteria:\n\nPatients with type 1 diabetes mellitus or secondary diabetes.\nPatients with serum creatinine > 1.5 mg/dl.\nAbnormal liver function tests (defined as value of transaminases > 3 times the upper value of normal or serum bilirubin higher than normal for the reference value for the laboratory).\nHistory of cholecystitis/ cholelithiasis/ cholecystectomy\nSeropositivity for HIV, HBsAg and hepatitis C virus (HCV).\nHistory of myocardial infarction or unstable angina in the previous 3 months.\nHistory of malignancy\nPatients with active infections."
      ],
      "EnrollmentCount": [
            "30"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "mesenchymal stem cell transplantation",
            "Control",
            "MNC's TRANSPLANTATION"
      ],
      "InterventionBrowseBranchAbbrev": [
            "Hypo",
            "All",
            "Micro",
            "Hemat",
            "Gast",
            "Vi"
      ],
      "InterventionBrowseBranchName": [
            "Hypoglycemic Agents",
            "All Drugs and Chemicals",
            "Micronutrients",
            "Hematinics",
            "Gastrointestinal Agents",
            "Vitamins"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M10819",
            "M7770",
            "M9517",
            "M172956",
            "M16710",
            "M8195",
            "M26150",
            "M16698",
            "M1693",
            "M1857",
            "T446",
            "T448",
            "T475"
      ],
      "InterventionBrowseLeafName": [
            "Metformin",
            "Folic Acid",
            "Insulin",
            "Insulin, Globin Zinc",
            "Vitamins",
            "Glucagon",
            "Glucagon-Like Peptide 1",
            "Vitamin B Complex",
            "Pioglitazone",
            "Vildagliptin",
            "Folic Acid",
            "Folate",
            "Vitamin B9"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .",
            "5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .",
            "20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months ."
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "mesenchymal stem cell transplantation",
            "control",
            "MNC's TRANSPLANTATION"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Other",
            "Biological"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "October 27, 2015"
      ],
      "LastUpdatePostDateType": [
            "Estimate"
      ],
      "LastUpdateSubmitDate": [
            "October 24, 2015"
      ],
      "LeadSponsorClass": [
            "OTHER_GOV"
      ],
      "LeadSponsorName": [
            "Postgraduate Institute of Medical Education and Research"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Chandigarh"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "India"
      ],
      "LocationFacility": [
            "Postgraduate Institute of Medical Education and Research"
      ],
      "LocationState": [
            "UT"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "160012"
      ],
      "MaximumAge": [
            "70 Years"
      ],
      "MinimumAge": [
            "30 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Efficacy and Safety of Autologous Bone Marrow Derived Stem Cell Transplantation in Patients With Type 2 Diabetes Mellitus"
      ],
      "OrgClass": [
            "OTHER_GOV"
      ],
      "OrgFullName": [
            "Postgraduate Institute of Medical Education and Research"
      ],
      "OrgStudyId": [
            "stem cell therapy in T2DM"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Post Graduate Institute of Medical Education and Research, Chandigarh",
            "Postgraduate Institute of Medical Education and Research, Chandigarh",
            "Postgraduate Institute of Medical Education and Research, Chandigarh"
      ],
      "OverallOfficialName": [
            "A Bhansali",
            "V Jha",
            "Neelam Marwaha"
      ],
      "OverallOfficialRole": [
            "Study Chair",
            "Principal Investigator",
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2",
            "Phase 3"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "December 2014"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [],
      "PrimaryOutcomeMeasure": [
            "Reduction of insulin requirement by \u2265 50% by the end of 6 months of autologous bone marrow derived stem cell transplantation and Improvement in Glucagon stimulated C - peptide levels and hyperglycemic clamp for assessment of beta cell function"
      ],
      "PrimaryOutcomeTimeFrame": [
            "6 months"
      ],
      "ReferenceCitation": [
            "Bhansali A, Upreti V, Khandelwal N, Marwaha N, Gupta V, Sachdeva N, Sharma RR, Saluja K, Dutta P, Walia R, Minz R, Bhadada S, Das S, Ramakrishnan S. Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cells Dev. 2009 Dec;18(10):1407-16. doi: 10.1089/scd.2009.0164.",
            "Bhansali S, Dutta P, Yadav MK, Jain A, Mudaliar S, Hawkins M, Kurpad AV, Pahwa D, Yadav AK, Sharma RR, Jha V, Marwaha N, Bhansali S, Bhansali A. Autologous bone marrow-derived mononuclear cells transplantation in type 2 diabetes mellitus: effect on \u03b2-cell function and insulin sensitivity. Diabetol Metab Syndr. 2017 Jul 4;9:50. doi: 10.1186/s13098-017-0248-7. eCollection 2017."
      ],
      "ReferencePMID": [
            "19686048",
            "28690682"
      ],
      "ReferenceType": [
            "background",
            "derived"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Postgraduate Institute of Medical Education and Research"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Anil Bhansali"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Professor and HOD"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Principal Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [],
      "SecondaryOutcomeMeasure": [],
      "SecondaryOutcomeTimeFrame": [],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "December 2012"
      ],
      "StartDateType": [],
      "StatusVerifiedDate": [
            "October 2015"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "January 3, 2013"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "December 30, 2012"
      ],
      "StudyFirstSubmitQCDate": [
            "January 2, 2013"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}